Indigenous Inactivated Vaccine Platform

TURKOVAC is Turkey's first indigenously developed vaccine, created by the Ministry of Health and Erciyes University using an inactivated SARS-CoV-2 platform. The vaccine demonstrated durable humoral and cellular immune responses up to 8 months in clinical studies published in 2025. Turkey conducted world-first heterologous studies administering TURKOVAC as a booster after mRNA vaccination, generating valuable immunological data.

The TURKOVAC program established Turkey's sovereign vaccine development pipeline — from virus isolation through clinical trials to mass production. While the pandemic urgency that drove TURKOVAC's development has passed, the capability infrastructure persists: Turkey is building a vaccine and biotech hub in Ankara, and Sinovac has opened its first overseas jointly invested vaccine production plant in Turkey, bringing mRNA technology and manufacturing expertise.

The strategic lesson of COVID-19 — that nations without vaccine sovereignty are dependent on the goodwill and supply priorities of producing nations — drives Turkey's continued investment in bio-pharmaceutical capability. The platform technologies developed for TURKOVAC (virus isolation, adjuvant development, clinical trial infrastructure) are transferable to other vaccine and therapeutic programs.